MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor that specifically targets the Mixed Lineage Kinase domain-like (MLKL) protein. It effectively prevents MLKL phosphorylation and oligomerization, which are critical steps in cell necrosis. Additionally, MLKL-IN-6 restrains the death of immune cells, diminishes the expression of adhesion factors, and exhibits low cytotoxicity. Furthermore, it impedes the activation of hepatic stellate cells, decreases levels of liver fibrosis markers, and exerts anti-fibrotic effects [1].